METHODS article

Front. Hum. Neurosci., 16 February 2022

Sec. Brain Imaging and Stimulation

Volume 15 - 2021 | https://doi.org/10.3389/fnhum.2021.743846

Evidence Mapping Based on Systematic Reviews of Repetitive Transcranial Magnetic Stimulation on the Motor Cortex for Neuropathic Pain

  • 1. Department of Kinesiology, Shanghai University of Sport, Shanghai, China

  • 2. School of Health Sciences, Duquesne University, Pittsburgh, PA, United States

  • 3. Centre for Regenerative Medicine and Health, Hong Kong Institute of Science & Innovation, Chinese Academy of Sciences Limited, Hong Kong, Hong Kong SAR, China

  • 4. Department of Rehabilitation Medicine, The Second School of Clinical Medicine, Xuzhou Medical University, Xuzhou, China

  • 5. Department of Physical Therapy, University of Toronto, Toronto, ON, Canada

  • 6. Department of Musculoskeletal Pain Rehabilitation, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, China

Article metrics

View details

4

Citations

4,1k

Views

1,6k

Downloads

Abstract

Background and Objective:

There is vast published literature proposing repetitive transcranial magnetic stimulation (rTMS) technology on the motor cortex (M1) for the treatment of neuropathic pain (NP). Systematic reviews (SRs) focus on a specific problem and do not provide a comprehensive overview of a research area. This study aimed to summarize and analyze the evidence of rTMS on the M1 for NP treatment through a new synthesis method called evidence mapping.

Methods:

Searches were conducted in PubMed, EMBASE, Epistemonikos, and The Cochrane Library to identify the studies that summarized the effectiveness of rTMS for NP. The study type was restricted to SRs with or without meta-analysis. All literature published before January 23, 2021, was included. Two reviewers independently screened the literature, assessed the methodological quality, and extracted the data. The methodological quality of the included SRs was assessed by using the A Measurement Tool to Assess Systematic Reviews (AMSTAR-2). Data were extracted following a defined population, intervention, comparison, and outcome (PICO) framework from primary studies that included SRs. The same PICO was categorized into PICOs according to interventions [frequency, number of sessions (short: 1–5 sessions, medium: 5–10 sessions, and long: >10 sessions)] and compared. The evidence map was presented in tables and a bubble plot.

Results:

A total of 38 SRs met the eligibility criteria. After duplicate primary studies were removed, these reviews included 70 primary studies that met the scope of evidence mapping. According to the AMSTAR-2 assessment, the quality of the included SRs was critically low. Of these studies, 34 SRs scored “critically low” in terms of methodological quality, 2 SR scored “low,” 1 SR scored “moderate,” and 1 SR scored “high.”

Conclusion:

Evidence mapping is a useful methodology to provide a comprehensive and reliable overview of studies on rTMS for NP. Evidence mapping also shows that further investigations are necessary to highlight the optimal stimulation protocols and standardize all parameters to fill the evidence gaps of rTMS. Given that the methodological quality of most included SRs was “critically low,” further investigations are advised to improve the methodological quality and the reporting process of SRs.

Introduction

Neuropathic pain (NP) is an ongoing and challenging condition due to its high morbidity rate of 7–10% in the general population; it usually results from lesions in the somatosensory nervous system, including the peripheral or central nervous system (Colloca et al., 2017). NP negatively impacts patients’ quality of life by reducing functional mobility, activities of daily living, and participation in social roles, which may lead to psychological problems (Kalia and O’Connor, 2005; Gromisch et al., 2020). The initial treatment applied to NP is generally pharmacotherapy, such as use of antidepressants, anticonvulsants, and opioids (Finnerup et al., 2015). However, even with complex treatment regimens, the results of pharmacological approaches remain unsatisfactory, and some may lead to adverse events, such as toxicity, gastrointestinal events, or increased risk of addiction or drug abuse (Papanas and Ziegler, 2016; Urits et al., 2019). Therefore, non-pharmacological interventions, which are considered safe and effective, have been used to treat NP. Repetitive transcranial magnetic stimulation (rTMS) technology is widely accepted at present as a non-pharmacological intervention for treating NP.

The rTMS technique uses a transient high-intensity magnetic field acting on the cerebral cortex to generate induced currents. It alters the action potential of cortical nerve cells, depolarizes neurons in the targeted brain region, and ultimately leads to neuroplastic changes (Paulus et al., 2013). Stimulation target, frequency, and number of sessions are considered critical variables for analgesic efficacy. In terms of stimulation target, the primary motor cortex (M1) is the most commonly used target of stimulation for clinical treatment and has been the most extensively studied. In the 2020 guidelines for rTMS (Lefaucheur et al., 2020), the M1 was recommended as Level A evidence (definitive efficacy) for the treatment of NP. However, clinical promotion is still limited to some extent due to the heterogeneity of treatment protocols, such as frequency and sessions, and effectiveness among various studies. The European Society of Neurology encourages studies to collect and summarize evidence on the factors affecting these techniques (Cruccu et al., 2016). SRs are a common method for synthesizing research evidence. Nonetheless, SRs tend to address more specific research and practice questions and cannot provide a comprehensive overview of rTMS for NP. For example, the following research gaps are unknown: (1) SRs focus on a specific stimulation type or specific pain type (such as pain after spinal cord injury, post-stroke, and diabetic neuropathy), while research on other pain types needs to be developed. (2) The frequency, duration, and other parameters of interventions collected by the SRs varied, and the large amount of evidence with a lack of summarization and classification may lead to clinicians’ confusion. (3) Differences in the quality between individual trials and SRs contributed to the heterogeneity of the evidence. The same primary study may be included in different SRs, which may yield various conclusions due to varying inclusion criteria.

A novel approach to evidence synthesis research called evidence mapping (Grant and Booth, 2009; Haddaway et al., 2016; Miake-Lye et al., 2016) has been developed. Evidence mapping is designed to provide an overview of a research area by including published SRs. Evidence mapping uses published SRs as units of analysis. In the population, intervention, control, and outcome (PICO) framework, evidence mapping extracts and categorizes these data from primary studies, which are included in the SRs. On the basis of the classification criteria, the obtained PICO is integrated into different PICOs, and the contribution of the number of primary studies related to that classification is also calculated to summarize the current interventions (Petersen et al., 2015). The characteristic of the evidence mapping method is to overcome the limitations of primary studies by using the selection of studies, effect size analysis, and bias evaluation of SRs. Considering that the quality of SRs affects the credibility of the evidence, the same primary studies may be included in SRs of different quality. Various conclusions may be drawn due to different inclusion criteria, such as random and double-blind bias. Therefore, evidence mapping uses AMSTAR-2 to evaluate the quality of SRs and the credibility of the results of SRs (Ballesteros et al., 2017; Madera Anaya et al., 2019). Evidence mapping can be translated into two visual products, namely, tables (general information tables and study-specific characteristic tables) and bubble plots (multidimensional composite presentation of classification criteria, quantity, and quality of evidence), which also provide a descriptive narrative summary of the results (Bragge et al., 2011; Haddaway et al., 2016).

Evidence mapping aims to summarize, identify, and analyze the current available evidence in SRs regarding rTMS on M1 for NP. Collecting and integrating data from primary studies on the basis of SRs provide breadth of evidence. Assessing the quality of SRs provides strength of evidence. This information is provided in a user-friendly manner that helps identify research gaps and assist evidence users in the decision-making process.

Materials and Methods

Study Design

Evidence was mapped on the basis of the methodology proposed by Global Evidence Mapping (Bragge et al., 2011). The study process was divided into four phases (Figure 1: Core tasks performed to map evidence).

FIGURE 1

Boundaries and Context of Evidence Mapping

Studies and guidelines related to NP were referred, and an expert with research background in NP was consulted to frame the evidence map. With the help of the expert, the specific terminology of the search strategy was confirmed and the possible evidence users (pain, neurology, psychiatry, anesthesiology, and rehabilitation) involved were discussed. On the basis of the above information, the eligibility criteria have been established for inclusion in the study. Studies containing rTMS for NP were considered eligible. Studies on patients with NP were included, whereas experimental subjects that were animals or healthy people were excluded. The intervention should be rTMS, and the comparison could be rTMS, sham rTMS, other treatments of relieving pain, or no treatment. The outcome should be pain measured with various clinically validated tools [e.g., Visual Analog Scale (VAS), Numerical Rating Scale (NRS), Short-Form McGill Pain Questionnaire, and Brief Pain Inventory]. Studies that did not address intervention outcomes, such as those that aimed to explore NP-related pathophysiology and focus on cost-effectiveness, were excluded. Studies that reported other outcomes (e.g., fatigue, motor function, spasticity, sensory function, and cognition) but pain were also excluded. Only SRs (with or without meta-analysis) were included as they provided reliable evidence.

Evidence Search and Selection

We conducted searches of systematic literature on PubMed, EMBASE, Epistemonikos, and The Cochrane Library Published before January 23, 2021. Medical subject headings (mesh terms), free-text terms, and synonymous terms available for NP and transcranial magnetic stimulation, such as “neuralgia,” “neurodynia,” “atypical neuralgia,” “nerve pain,” and “stump neuralgia,” were combined. Literature published in non-English languages was excluded. References of the relevant studies that met the inclusion criteria were added to potential additional reviews. The details of the search strategies are reported in Supplementary Material 1. EndNote (version X9) was applied to manage the search results. Duplicate SRs were removed, and two reviewers (YZa and XL) independently screened the titles and abstracts to exclude irrelevant studies. Full-text studies were obtained and reviewed to make a terminal decision. Any disagreements in the decision-making process were resolved through negotiation or by discussion with a third reviewer (YoZ).

Data Analysis

A data extraction table was designed to record the main characteristics and compare the methodological differences of the included SRs. Two authors (YZa and XL) assessed the methodological quality and extracted data independently. Any difference of opinions was discussed with the third author (YoZ). The original authors were contacted for missing information when necessary. Data were grouped into three categories:

(a) The Assessment Methodological Quality for Systematic Reviews (AMSTAR-2) was used to assess the methodological quality of SRs (Shea et al., 2017). AMSTAR-2 is a practical tool used to assess the quality of SRs that include randomized or non-randomized studies of healthcare interventions or both. It has 16 items, with an overall rating based on weaknesses in critical domains (items: 2, 4, 7, 9, 11, 13, and 15). In brief, the evaluation results of the SRs are generally divided into the following four categories: “High,” no critical weakness and no more than one non-critical weakness; “Moderate,” no critical weakness and more than one non-critical weakness; “Low,” one critical flaw with or without non-critical weaknesses; and “Critically low,” more than one critical flaw with or without non-critical weaknesses.

(b) The following characteristics of SRs were extracted: authors, years of publication, types of SR (with or without meta-analysis), objectives, dates of search, sample sizes, designs, and numbers of included studies.

(c) The PICO framework was used to extract data from primary studies included in the SRs. The four key components are populations, intervention, comparison, and outcomes. Details including population characteristics (e.g., NP related to spinal cord injury, post-stroke symptoms, and complex regional pain syndrome), interventions (e.g., target area, frequency, and intensity of transcranial magnetic stimulation), comparative measures (e.g., placebo and sham stimulation), and outcomes were extracted. The obtained data of PICO from primary studies in SRs were classified into different groups based on similar characteristics (population; interventions: frequency, session, and intensity; control group; and outcome scale).

For descriptive purposes, the effect of rTMS on NP reported by the SR authors was grouped into the following five categories on the basis of the previously reported criteria: “Potentially better,” the conclusions reported rTMS as more beneficial than the control group; “Mixed results,” the same primary study had different findings among different studies (e.g., some studies found no difference in rTMS compared with the control group in the same population, whereas others found potential benefits of transcranial magnetic stimulation over the control group); “Unclear,” insufficient evidence to draw definitive conclusions about the effectiveness of rTMS on pain; “No difference,” the conclusions provided evidence of no difference between intervention and control; and “Potentially worse,” the conclusions reported TMS as less beneficial than the control group. The same primary study may be included in multiple SRs. If the primary study has multiple consistent results, it would be added to the appropriate group, and multiple conflicting findings were included in the “Mixed Results” group (Miake-Lye et al., 2019).

Reporting Synthesized Findings

Each clinical question addressed in each included review was adapted into a PICO format that specified the types of participants, interventions (or comparison), and outcomes. Evidence mapping allows the reader to visualize any gaps in the literature base, with results presented in the form of tables and graphs.

  • (a)

    The basic characteristics, quality assessment of the included SRs, and characteristics of all integrated PICOs were described in tables.

  • (b)

    A heat map was used to present the quality of the included SRs.

  • (c)

    Graphical display was provided through bubble plots. The bubble plot displayed information in four dimensions: (1) bubble size (number of articles), the size of each bubble is proportional to the number of individual trials included in the SRs; (2) bubble color (research characteristics), bubbles labeled with different colors indicate different PICOs; (3) X-axis (effect of TMS on NP), the classification of authors’ conclusions represented on the X-axis (“potentially better,” “mixed results,” “unclear,” “no difference,” and “worse”); and (4) Y-axis (AMSTAR-2 evaluation results), four different colors were used to indicate study quality, with red indicating critically low, orange indicating low, yellow indicating moderate, and green indicating high quality.

Results

Selected Studies

This retrieval yielded 125 records. Another 11 articles were added from the references that met the inclusion criteria. After duplicates were removed, 97 articles remained for screening of the titles and abstracts. Subsequently, 44 articles were excluded after the screening. In the remaining 53 articles, 13 were excluded after full-text reviews. Finally, 38 articles met the eligibility criteria (Figure 2). The list of excluded studies along with exclusion rationales can be found in Supplementary Material 2.

FIGURE 2

Methodological Quality of Systematic Reviews

According to the AMSTAR-2 criteria, 34 SRs scored “critically low,” 2 SR scored “low,” 1 SR scored “moderate,” and 1 SR scored “high” in terms of methodological quality (Figure 3). The most frequent drawbacks were as follows: no mention of the protocol in the systematic overview, no description of the rationale for the study designs included in the review, no report of excluded studies or reasons for exclusion, and no statement of funding for the included studies. The detailed assessment process is provided in Supplementary Material 3.

FIGURE 3

Characteristics of the Included Systematic Reviews

Table 1 shows the characteristics of the included SRs. All SRs were published between 2009 and 2020. Among the 38 included SRs, 17 SRs conducted a meta-analysis. The number of included studies ranged from 3 to 131, and they were conducted between 2001 and 2020. Each SR included patients ranging from 97 to 15,776. Six SRs did not report or incompletely reported the designs of the included individual studies. All studies reported study designs, and a total of 678 randomized controlled trials (RCTs) accounted for 86% of the included studies in all SRs. Of all SRs, 18 SRs included only RCTs, 15 SRs included patients with NP with different underlying causes, and 25 were exclusively conducted on NP with specific etiologies or due to a single disease. Six SRs included pain after spinal cord injury (SCI), another 5 SRs included central post-stroke pain (P), 3 SRs included phantom limb pain (PLP), 2 SRs included migraine, 2 SRs included complex regional pain syndrome (CRPS), 2 SRs included headache, 1 SR included diabetic peripheral neuropathy (DPN), 1 SR included multiple sclerosis (MS), and 1 SR included orofacial pain (OFP). As for the intervention, 13 SRs only assessed rTMS, 12 SRs assessed other non-invasive stimulations, 3 SRs assessed neuromodulation techniques, 4 SRs assessed non-pharmacological interventions, 5 SRs assessed pharmacological and non-pharmacological management of NP, and 1 SR assessed non-invasive brain stimulation combined with exercise.

TABLE 1

Author and yearStudy designSearch dateObjectiveNumber of studies includedDesign and number of included studiesParticipants (n)
Zucchella et al., 2020SRFebruary 2020To evaluate the effect of non-invasive brain and spinal cord stimulation in the treatment of pain in multiple sclerosis9RCT: 1
NCS: 6
FP: 1
CR: 1
175
Zeng et al., 2020SRMAugust 2019To evaluate the effect of NINM in relieving pain intensity and improving nerve conduction velocity in patients with diabetic peripheral neuropathy20RCT: 18
QE: 2
1167
Yu et al., 2020SRMJanuary 2019To investigate the effect of non-invasive brain stimulation on NP in patients with SCI11RCT: 11274
Yang and Chang, 2020SRJune 2019To explore the effect of rTMS on the control of various types of pain conditions106RCT: 69
OLT: 16
CR: 21
3264
Shen et al., 2020SRMNovember 2019To evaluate the effect of non-invasive brain stimulation (rTMS and tDCS) on NP after SCI10RCT: 10214
Pacheco-Barrios et al., 2020SRMFebruary 2019To assess the efficacy of neuromodulation techniques for the treatment of PLP in adults14RCT: 9
QE: 5
261
Moisset et al., 2020aSRMJuly 2020To investigate the efficacy of neurostimulation techniques in migraine38RCT: 382899
Moisset et al., 2020bSRAugust 2019To propose all the alternative treatment options for NP131RCT: 13115776
Liampas et al., 2020aSRMNovember 2019To describe the prevalence and characteristics of CPSP and investigate the relevant management methods69NRNA
Liampas et al., 2020bSRApril 2020To assess the effect of non-pharmacological interventions in the management of peripheral NP18RCT: 13
OLT: 5
1613
Gatzinsky et al., 2020SRJune 2019To review primary research regarding the efficacy and safety of rTMS on M132RCT: 24
CS: 8
682 (RCT)
Chang et al., 2020SRMFebruary 2020To assess the effectiveness of rTMS in the treatment of CRPS-related pain3RCT: 1
Prospective observational studies: 2
41
Cardenas-Rojas et al., 2020SRMNovember 2019To assess the efficacy and safety of NIBS combined with exercise in the treatment of chronic pain8RCT: 8219
Aamir et al., 2020SRJune 2019To evaluate the effect of rTMS in the management of peripheral NP12RCT: 5
CS: 2
CR: 5
188
Stilling et al., 2019SRSeptember 2018To review the use of TMS and tDCS for specific headache disorders34Randomized trials: 20
NRC/Prospective cohort/OLT: 14
1787
Ramger et al., 2019SR2018To evaluate the efficacy of rTMS and tDCS in the treatment of CPSP6RCT: 1
Prospective cohort: 1
CS: 2
Cross-over: 2
109
Nardone et al., 2019SRApril 2018To evaluate the efficacy of TMS in treating patients with painful and non-painful phantom phenomena18NRNA
Hamid et al., 2019SR2018To evaluate the effect of rTMS on chronic refractory pain, especially in adults with central NP12RCT: 12350
Feng et al., 2019SRMSeptember 2018.To evaluate the efficacy of rTMS and tDCS in RCTs in the treatment of migraine9RCT: 9276
Akyuz and Giray, 2019SRAugust 2017To assess the effectiveness and safety of rTMS and tDCS in the treatment of PLP4RCT: 497
O’Connell et al., 2018SRMOctober 2017To assess the efficacy of non-invasive cortical stimulation techniques chronic pain94RCT: 942983
Herrero Babiloni et al., 2018SRNRTo evaluate the analgesic effect of TMS and tDCS in the treatment of different etiologies of chronic OFP14RCT: 14228
Lan et al., 2017SRMApril 2017To evaluate the efficacy of TMS in the treatment of migraine5RCT: 5313
Kumru et al., 2017SRAugust 2015To assess the role of rTMS or peripheral magnetic stimulation for the treatment of NP39NR892
Goudra et al., 2017SRMNRTo evaluate the effect of rTMS in the management of chronic pain9RCT: 6
Prospective observational: 3
183
Gao et al., 2017SRMMarch 2016To assess the analgesic effect of rTMS in patients with SCI-related NP6RCT: 6127
Cragg et al., 2016SRMMay 2015To explore the predictors of placebo responses in central NP clinical trials39RCT: 391153
Chen et al., 2016SRSeptember 2015To evaluate the antalgic effects of NIPMs on CPSP16NA184
Mulla et al., 2015SRDecember 2013To provide an overview of the evidence-based management of CPSP8RCT: 8459
Jin et al., 2015SRMDecember 2014To evaluate the optimal parameters of rTMS for NP25RCT: 20
Self-controlled: 5
589
Galhardoni et al., 2015SR2014To review the literature on the analgesic effects of rTMS in chronic pain33RCT: 33842
Moreno-Duarte et al., 2014SR2012To evaluate the effectiveness and safety of neural stimulation techniques for the treatment of SCI pain10RCT: 8
OLT: 2
307
Boldt et al., 2014SRMMarch 2011To review the available research evidence to explore the effectiveness of non-pharmacological interventions in patients with SCI16RCT: 16616
Mehta et al., 2013SRApril 2011To review the literature on non-pharmacological treatment of post-SCI pain17RCT: 9
Prospective controlled trial: 2
CS: 1
Pre-post: 5
433
Cossins et al., 2013SRFebruary 2012To explore therapeutic methods for effective management of CRPS29RCT: 29NR
Zaghi et al., 2011SRJanuary 2010To review the analgesic efficacy of TMS and tDCS and to discuss potential mechanisms of action18NR413
Leung et al., 2009SRMAugust 2007To evaluate the overall analgesic effect of rTMS in M1 for NP and evaluate the effect of treatment parameters. such as pulse, frequency, and number of sessions on the treatment effect5RCT: 5149
Kumar et al., 2009SRSeptember 2008To review pathophysiology and treatment of CPSPNANANA

Characteristics of included systematic reviews.

SR, systematic review; SRM, systematic review with meta-analysis; NINM, non-invasive neuromodulation; NP, neuropathic pain; SCI, spinal cord injury; rTMS, repetitive transcranial magnetic stimulation; CPSP, central poststroke pain; tDCS, transcranial direct current stimulation; PLP, phantom limb pain; M1, motor cortex; CRPS, complex regional pain syndrome; NIBS, non-invasive brain stimulation; TMS, transcranial magnetic stimulation; OFP, orofacial pain; NIPMs, non-invasive physical modalities; RCT, randomized controlled trial; NCS, non-controlled trial; FP, feasibility pilot; CR, case report; QE, quasi-experiment; OLT, open-label trial; NR, not reported. NRT, non-randomized trial; CS, case series; NA, not available.

Characteristics of Population, Intervention, Comparison, and Outcomes From Systematic Reviews

After merging the duplicate primary studies included in the 38 SRs, 70 primary studies were integrated into 19 PICO groups based on the PICO characteristics. Studies that did not provide the mandatory parameter information were not included in the PICOs. Among the included SRs, populations with NP were from various diseases and etiologies, and the treatment protocols adopted various parameters, including frequency, sessions, and pulses. Sham stimulation or placebo was the most common intervention in the control group of rTMS on the M1. The primary outcome of the included studies was self-reported subjective nociception. VAS and NRS were the most commonly validated pain assessment scales. The details of the characteristics are enumerated in Supplementary Material 4.

As a result of unavoidable heterogeneity of the rTMS protocol among studies, classifying and categorizing all parameters can be difficult. Thus, the classification of PICO focused on interventions and comparison, as well as the population involved and outcome assessments, as presented in Table 2. We use Figure 4 to explain the connection between the bubble polt and Table 2. In terms of interventions, we classified them to frequency and session of rTMS, as they have been shown to influence the analgesic effects and are identified as clinically significant factors (Ahmed et al., 2012; O’Connell et al., 2018; Gatzinsky et al., 2020; Pacheco-Barrios et al., 2020). High and low frequency of rTMS can induce transient excitatory and inhibitory effects, respectively (Klein et al., 2015). Sessions of rTMS are considered an important factor in maintaining the effects. The characteristics of the interventions were categorized based on frequency (low or high frequency) and number of sessions (short: 1–5 sessions, medium: 5–10 sessions, and long: >10 sessions).

TABLE 2

PICOS
number
PICOs in bubble chartInterventionParametersComparisonPopulationOutcomesIncluded SRsPrimary studies included in SRsConclusion


Frequency (Hz)Session scheduleRCTObservationNumber of primary studiesNumber of SRs involving the Quality (high/moderate/low/critically low) of primary studies
150 Hz, short sessions versus sham rTMSrTMS50 Hz1 sessionSham rTMSChronic OFPVASHerrero Babiloni et al., 2018Kohútová et al., 201710/0/0/1Potentially better
rTMS50 Hz1 sessionSham rTMSChronic OFPVASHerrero Babiloni et al., 2018Kohútová et al., 201710/0/0/1No difference (long term)
220 Hz, long sessions versus sham rTMSrTMS20 Hz11 sessionsSham rTMSMixed NPVASYang and Chang, 2020Pommier et al., 201610/0/0/1Potentially better
320 Hz, medium sessions versus sham rTMSrTMS20 Hz10 sessionsSham rTMSPelvic pain (urinary bladder pain syndrome)/cancer and malignant NPVASGatzinsky et al., 2020; Moisset et al., 2020b; Yang and Chang, 2020Khedr et al., 2015; Cervigni et al., 201820/0/0/2Potentially better
rTMS20 Hz10 sessionsSham rTMSCancer and malignant NPVASJin et al., 2015; Gatzinsky et al., 2020; Moisset et al., 2020b; Yang and Chang, 2020Jin et al., 2015; Khedr et al., 201520/0/0/2No difference (1 month later)
420 Hz, short sessions versus sham rTMSrTMS20 Hz5 sessionsSham rTMSLBP, non-specified OFP, TN after dental or neural surgery, atypical facial pain, CPSP, TN, PLP, Alzheimer, TGNP, and IBSVASKumar et al., 2009; Leung et al., 2009; Zaghi et al., 2011; Galhardoni et al., 2015; Jin et al., 2015; Chen et al., 2016; Goudra et al., 2017; Kumru et al., 2017; Herrero Babiloni et al., 2018; O’Connell et al., 2018*; Akyuz and Giray, 2019; Hamid et al., 2019; Nardone et al., 2019; Aamir et al., 2020; Gatzinsky et al., 2020; Liampas et al., 2020a; Moisset et al., 2020b; Pacheco-Barrios et al., 2020]; Yang and Chang, 2020Khedr et al., 2005*; Ahmed et al., 2011*, 2012; Fricova et al., 2013; Melchior et al., 2014; Ambriz-Tututi et al., 2016114/0/0/11Potentially better
rTMS20 Hz4 sessionsSham rTMSCPSP, SCINRSYang and Chang, 2020Quesada et al., 2018Potentially better
rTMS20 Hz2 sessionsSham rTMSMixed NPVASGalhardoni et al., 2015; Kumru et al., 2017; O’Connell et al., 2018*; Gatzinsky et al., 2020; Yang and Chang, 2020Andre-Obadia et al., 2008*Potentially better (posteroanterior orientation of the coil)
rTMS20 Hz2 sessionsSham rTMSMixed NP and TNNRSHerrero Babiloni et al., 2018; Hamid et al., 2019; Yang and Chang, 2020Andre-Obadia et al., 2018Potentially better (with M1 hand)
rTMS20 Hz1 sessionSham rTMSChronic neuropathic pain (mixed), CPSP, SCI, BPL, and TGNPNRSJin et al., 2015; Kumru et al., 2017; O’Connell et al., 2018*; Hamid et al., 2019; Gatzinsky et al., 2020Andre-Obadia et al., 2011*, 2014Potentially better
rTMS20 Hz5 sessionsSham rTMSDPNVASGalhardoni et al., 2015; Jin et al., 2015; Kumru et al., 2017; O’Connell et al., 2018*; Aamir et al., 2020; Liampas et al., 2020b; Moisset et al., 2020b; Yang and Chang, 2020; Zeng et al., 2020Onesti et al., 2013*21/0/0/2Mixed
rTMS20 Hz1 sessionSham rTMSLBPPain intensityZaghi et al., 2011; Galhardoni et al., 2015Johnson et al., 2006Mixed
rTMS20 Hz5 sessionsSham rTMSRectal sensitivity in IBSGoudra et al., 2017Melchior et al., 201353/0/0/5No difference
rTMS20 Hz3 sessionsSham rTMSMixed NPVASZaghi et al., 2011; Galhardoni et al., 2015; Jin et al., 2015; O’Connell et al., 2018*; Gatzinsky et al., 2020; Yang and Chang, 2020Andre-Obadia et al., 2006*No difference
rTMS20 Hz2 sessionsSham rTMSMixed NPVASGalhardoni et al., 2015; Jin et al., 2015; Kumru et al., 2017; O’Connell et al., 2018*Andre-Obadia et al., 2008*No difference (lateromedial orientation of the coil)
rTMS20 Hz2 sessionsSham rTMSMixed NPNRSHerrero Babiloni et al., 2018Andre-Obadia et al., 2018No difference (with M1 face)
rTMS20 Hz1 sessionSham rTMSMixed NPVASLeung et al., 2009; Zaghi et al., 2011; Jin et al., 2015; Galhardoni et al., 2015; O’Connell et al., 2018*; Yang and Chang, 2020Rollnik et al., 2002*No difference
510 Hz, long sessions versus sham rTMSrTMS10 Hz15 sessionsSham rTMSPHNVASMoisset et al., 2020bPei et al., 201920/0/0/2Potentially better
rTMS10 Hz12 sessionsSham rTMSMigraineLan et al., 2017Shehata et al., 2016Potentially better
rTMS10 Hz12 sessionsSham rTMSMigraineVASStilling et al., 2019; Yang and Chang, 2020Shehata et al., 201610/0/0/1Mixed
610 Hz, medium sessions versus sham rTMSrTMS10 Hz10 sessionsSham rTMSSCI, chronic central pain after mild traumatic brain injury, thalamic pain, hemiplegic shoulder pain, PHN, PLP, and CPSPNRS, VASCragg et al., 2016; Gao et al., 2017; O’Connell et al., 2018*; Akyuz and Giray, 2019; Nardone et al., 2019; Aamir et al., 2020; Gatzinsky et al., 2020; Moisset et al., 2020b; Shen et al., 2020; Yang and Chang, 2020Yilmaz et al., 2014*; Ma et al., 2015; Malavera et al., 2016; Choi et al., 2018; Choi and Chang, 2018Lin et al., 201871/0/0/7Potentially better
rTMS10 Hz9 sessionsSham rTMSMixed NPVASYang and Chang, 2020Lawson et al., 2018Potentially better
rTMS10 Hz10 sessionsSham rTMSCRPSVASCossins et al., 2013; Galhardoni et al., 2015; Jin et al., 2015; O’Connell et al., 2018*; Cardenas-Rojas et al., 2020; Chang et al., 2020; Gatzinsky et al., 2020; Yang and Chang, 2020Picarelli et al., 2010*11/0/0/1Mixed
rTMS10 Hz10 sessionsSham rTMSSCIVASGao et al., 2017; Gatzinsky et al., 2020; Shen et al., 2020; Yang and Chang, 2020Yilmaz et al., 201431/0/0/2No difference (<6 weeks)
rTMS10 Hz10 sessionsSham rTMSPLPVASO’Connell et al., 2018*; Aamir et al., 2020; Gatzinsky et al., 2020; Moisset et al., 2020b; Pacheco-Barrios et al., 2020; Yang and Chang, 2020Malavera et al., 2013**, 2016No difference (30 days)
rTMS10 Hz10 sessionsSham rTMSMigraineTotal HA days; overall HA indexStilling et al., 2019Teo et al., 201410/0/0/1Potentially worse
710 Hz, short sessions versus sham rTMSrTMS10 Hz5 sessionsSham rTMSMixed refractory neuropathic pain, radiculopathy, CPSP, mixed NP, pelvic pain, and facial NPVAS, NRSKumru et al., 2017; O’Connell et al., 2018*; Gatzinsky et al., 2020; Yang and Chang, 2020Lang et al., 2014; Nurmikko et al., 2016*Pinot-Monange et al., 2019185/0/0/18Potentially better
rTMS10 Hz3 sessionsSham rTMSMixed NP, MBTI-HA, chronic migraine, CPSP, SCI, NTL, BPL, PLP, PNI, TGNP, and migraineVAS, NRSZaghi et al., 2011; Galhardoni et al., 2015; Jin et al., 2015; Kumru et al., 2017; Gao et al., 2017; O’Connell et al., 2018*; Feng et al., 2019; Stilling et al., 2019; Gatzinsky et al., 2020; Yang and Chang, 2020Lefaucheur et al., 2006*, 2008*; Saitoh et al., 2007*; Misra et al., 2013, 2017; Kalita et al., 2016; Leung et al., 2016Lefaucheur et al., 2006, 2012; Misra et al., 2013; Kalita et al., 2017Potentially better
rTMS10 Hz1 sessionSham rTMSMigraine, CPSP, SCI, PNP, mixed NP, CPSP, SCI, trigeminal nerve lesion (failure of TN surgery), BPL, and TGNIVASKumar et al., 2009; Leung et al., 2009; Zaghi et al., 2011; Galhardoni et al., 2015; Chen et al., 2016; Gao et al., 2017; Kumru et al., 2017; Herrero Babiloni et al., 2018; O’Connell et al., 2018*; Gatzinsky et al., 2020; Moisset et al., 2020a; Yang and Chang, 2020Lefaucheur et al., 2004*, 2011; Misra et al., 2013, 2017Potentially better
rTMS10 Hz5 sessionsSham rTMSSCINRSZaghi et al., 2011; Mehta et al., 2013; Boldt et al., 2014#; Moreno-Duarte et al., 2014; Galhardoni et al., 2015; Jin et al., 2015; Cragg et al., 2016; Gao et al., 2017; Goudra et al., 2017; Kumru et al., 2017; O’Connell et al., 2018*; Gatzinsky et al., 2020; Moisset et al., 2020b; Shen et al., 2020; Yang and Chang, 2020; Yu et al., 2020Kang et al., 2009*#86/1/0/8Mixed
rTMS10 Hz3 sessionsSham rTMSMixed NP, CPSP, and BPLVASJin et al., 2015; Gao et al., 2017; Kumru et al., 2017; O’Connell et al., 2018*; Yang and Chang, 2020Lefaucheur et al., 2001b*Lefaucheur, 2003Mixed
rTMS10 Hz2 sessionsSham rTMSMixed NP, radiculopathy, TN after surgery, and atypical facial pain after dental surgeryVASHerrero Babiloni et al., 2018; Yang and Chang, 2020Ayache et al., 2016Mixed
rTMS10 Hz1 sessionSham rTMSSCI, CRPS, mixed NP, CPSP, and SCIVAS, NRSCossins et al., 2013; Galhardoni et al., 2015; Jin et al., 2015; Chen et al., 2016[; Cragg et al., 2016; Gao et al., 2017; Kumru et al., 2017; Herrero Babiloni et al., 2018; O’Connell et al., 2018*; Chang et al., 2020; Gatzinsky et al., 2020; Shen et al., 2020; Yang and Chang, 2020Lefaucheur et al., 2001a*; Pleger et al., 2004*; Lefaucheur et al., 2006*; Jetté et al., 2013*Mixed
85 Hz, long sessions versus sham rTMSrTMS5 Hz15 sessionsSham rTMSPHNVASMoisset et al., 2020bPei et al., 201920/0/1/2Potentially better
rTMS5 Hz12 sessionsSham rTMSCPSPVASKumru et al., 2017; Ramger et al., 2019&; Yang and Chang, 2020Kobayashi et al., 2015&Potentially better (up to 8 weeks)
95 Hz, medium sessions versus sham rTMSrTMS5 Hz10 sessionsSham rTMSSCI, mixed NP, CPSP, BPL, PLP, TGNP, and PNIVASZaghi et al., 2011; Mehta et al., 2013; Boldt et al., 2014#; Moreno-Duarte et al., 2014; Galhardoni et al., 2015; Jin et al., 2015; Mulla et al., 2015; Chen et al., 2016; Cragg et al., 2016; Gao et al., 2017; Kumru et al., 2017; Herrero Babiloni et al., 2018; O’Connell et al., 2018*; Gatzinsky et al., 2020; Moisset et al., 2020b; Shen et al., 2020; Yang and Chang, 2020; Yu et al., 2020Defrin et al., 2007*#; Hosomi et al., 2013*22/1/0/2Mixed
105 Hz, short sessions versus sham rTMSrTMS5 Hz5 sessionsSham rTMSMixed NPVASHamid et al., 2019; Liampas et al., 2020a; Yang and Chang, 2020Shimizu et al., 201743/0/1/4Potentially better
rTMS5 Hz3 sessionsSham rTMSCPSP,SCI, PL, BPL, and PNIVASJin et al., 2015; Gao et al., 2017; Kumru et al., 2017; O’Connell et al., 2018*; Yang and Chang, 2020Saitoh et al., 2007*Potentially better
rTMS5 Hz1 sessionSham rTMSCPSPVAS or NRSGalhardoni et al., 2015; Jin et al., 2015; Kumru et al., 2017; Hamid et al., 2019; Ramger et al., 2019&; Yang and Chang, 2020Hosomi et al., 2013*; Matsumura et al., 2013*&Potentially better
rTMS5 Hz1 sessionSham rTMSPLPVAS or NRSGalhardoni et al., 2015; O’Connell et al., 2018*; Pacheco-Barrios et al., 2020Irlbacher et al., 2006*1/0/0/1No difference
111 Hz, short sessions versus sham rTMSrTMS1 Hz3 sessionsSham rTMSMixed NP, CPSP, SCI, PNP, PLP, BPL, and TGNPVAS, NRSLeung et al., 2009; Zaghi et al., 2011; Galhardoni et al., 2015; Gao et al., 2017; Kumru et al., 2017; O’Connell et al., 2018*; Yang and Chang, 2020Andre-Obadia et al., 2006*; Saitoh et al., 2007*; Lefaucheur et al., 2008*44/0/0/4No difference
rTMS1 Hz1 sessionSham rTMSPLPVAS orNRSGalhardoni et al., 2015; O’Connell et al., 2018*; Pacheco-Barrios et al., 2020Irlbacher et al., 2006*No difference
120.5 Hz, short sessions versus sham rTMSrTMS0.5 Hz3 sessionsSham rTMSMixed NP, CPSP, and BPLVASZaghi et al., 2011; Galhardoni et al., 2015; Jin et al., 2015; Kumru et al., 2017; Yang and Chang, 2020Lefaucheur et al., 2001b10/0/0/1Mixed
13rTMS on M1 versusrTMS on S1, SMA, PMC, and shamrTMS on M1 area5 Hz2 sessionsrTMS on S1,SMA,PMC areaCPSP, SCI, TGNI, PNI, and RAVASKumru et al., 2017Saitoh et al., 200610/0/0/1Potentially better
rTMS on M1 area5 Hz4 sessionsrTMS on S2,SMA,PMC areaMixed NP, CPSP, SCI, TGNP, and PNPVASLeung et al., 2009; Galhardoni et al., 2015; Jin et al., 2015; Chen et al., 2016; Kumru et al., 2017; O’Connell et al., 2018*; Gatzinsky et al., 2020; Yang and Chang, 2020Hirayama et al., 2006*11/0/0/1Mixed
14bilateral M1 versus unilateral M1rTMS:bilateral M110 Hz1 sessionrTMS, unilateral M1TNYang and Chang, 2020Henssen et al., 201910/0/0/1Potentially better
15Single rTMS versus 5 rTMS sessionsrTMS10 Hz1 sessionrTMS, 5 sessionsCRPSVAS, NRSChang et al., 2020; Yang and Chang, 2020Gaertner et al., 201810/0/0/1Mixed
163 true rTMS versus 1 true + 2 sham rTMSrTMS10 Hz3 sessions true1 true sessions and 2 sham sessionsMigraineVASStilling et al., 2019Misra et al., 201710/0/0/1Potentially better
rTMS10 Hz3 sessions true1 true sessions and 2 sham sessionsMigraineVASStilling et al., 2019; Moisset et al., 2020aKalita et al., 201610/0/0/1No difference
17rTMS versus BTX-A InjectionrTMS10 Hz12 sessionsBTX-A injectionMigraineYang and Chang, 2020Shehata et al., 201610/0/0/1Unclear
rTMS10 Hz12 sessionsBTX-A 31 to 39 sitesMigraineVASStilling et al., 2019; Moisset et al., 2020aShehata et al., 201610/0/0/1No difference
rTMS10 Hz12 sessionsBTX-A 31 to 39 sitesMigraineVASStilling et al., 2019; Moisset et al., 2020aShehata et al., 201610/0/0/1Potentially worse (at week 12)
18rTMS + tDCS versussham rTMS and tDCSrTMS and tDCS10 Hz3 sessionsSham rTMS and2-mA tDCSRadiculopathyNRSO’Connell et al., 2018; Aamir et al., 2020; Gatzinsky et al., 2020; Yang and Chang, 2020*Attal et al., 2016*11/0/0/1Mixed
19rTMS + TBS versus rTMSrTMS+ TBS10 Hz1 sessionrTMSTGNP, CPSP, and SCIVASGalhardoni et al., 2015; Kumru et al., 2017Lefaucheur et al., 201210/0/0/1Potentially better

PICOs included in systematic reviews.

PICO, population, intervention, control group, outcome; RCT, Randomized controlled trial; rTMS, Repetitive transcranial magnetic stimulation; M1, Motor cortex; S1, Primary somatosensory cortex; SMA, Supplementary motor cortex; PMC, Premotor cortex; BTX-A, Botulinum toxin type A; tDCS, Transcranial direct current stimulation; TBS, Theta-burst stimulation; OFP, Orofacial pain; NP, Neuropathic pain; LBP, Low back pain; TN, Trigeminal neuralgia; CPSP, Central post-stroke pain; PLP, Phantom limb pain; MBTI-HA, Mild traumatic brain injury related headache; NTL, Nerve trunk lesion; TGNP, Trigeminal neuropathic pain; IBS, Irritable bowel syndrome; SCI, Spinal cord injury; BPL, Brachial plexus lesion; DPN, Diabetic peripheral neuropathy; PHN, Postherpetic neuralgia; PNI, peripheral nerve injury; PNP, peripheral neuropathic pain; TGNI, trigeminal nerve injury; RA, root avulsion; VAS, Visual analog scale; NRS, Numerical rating scale.

Notes: short, 1–5 sessions, medium, 5–10 sessions, long, >10 sessions.

In the [Included SRs], high-quality SRs are marked as *, moderate quality SRs are marked as #, low-quality SRs are marked as &, and the rest are critically-low-quality SRs.

In the [Primary studies included in SRs], *, included by high and critically-low-quality SRs; **, Only included by high-quality SRs; #, Included by moderate and critically-low-quality SRs; &, Included by low and critically-low-quality SRs.

In the [Number of SRs involving the quality (high/moderate/low/critically low) of primary studies], Taking the 9th PICOs (5 Hz, medium sessions vs. sham rTMS), as an example, a total of 2 primary studies were involved. The meaning of 2/1/0/2 is shown in Figure 4.

FIGURE 4

The key characteristics of PICOs are listed in Supplementary Material 5. A total of 19 PICOs were categorized based on stimulation target, frequency, and session (short, medium, and long). On the basis of the stimulation target, 17 PICOs used high-frequency rTMS (>1 Hz), and 2 used low-frequency rTMS (<1 Hz). In terms of the number of sessions, 1–5 sessions were considered short sessions, 6–10 were medium sessions, and more than 10 were regarded as long sessions. Twelve PICOs had short sessions, three had medium sessions, and four had long sessions. In addition, 12 PICOs used the same sessions of sham stimulation or placebo as a control to study the effectiveness of rTMS in patients with NP. Two PICOs studied the effects of different sessions of rTMS, while other PICOs involved different stimulation areas: M1 unilateral stimulation versus bilateral stimulation, rTMS compared with botulinum toxin injection, rTMS compared with transcranial direct current stimulation (tDCS), or rTMS combined with theta-burst stimulation. The PICOs were concentrated in the following characteristics: 20 Hz, short-term sessions versus sham stimulation (11 PICOs), and 10 Hz, short-term sessions versus sham stimulation (18 PICOs).

Specific Findings From Systematic Reviews in Evidence Mapping

The evidence map of rTMS for NP is presented in Figure 5. The bubble diagram is a visual display of data represented in Supplementary Material 5. We integrated similar intervention characteristics from primary studies into PICOs. In the bubble chart, different colors indicate varying PICOs. Each bubble was plotted in accordance with the conclusion of the effect of rTMS on NP (X-axis) and the quality of the related SRs (Y-axis), while the size of bubbles represented the number of primary studies included in PICOs. The evidence tables (Supplementary Material 5) provided details of the included SRs (Supplementary Material 4). Some primary studies may be included in multiple SRs. If SRs synthesized different conclusions for the same primary study, the same PICOs would appear in different classifications on the X-axis. If the same primary study was included by SRs of different quality, the same PICOs would appear in different classifications on the Y-axis. Evidence mapping showed that 5–20 Hz, high-frequency rTMS of M1 with short (1–5), medium (6–10), or long (>10) sessions usually lead to “potentially better” treatment effects compared with sham stimulation, although some had transient effects. By contrast, the synthesis results for the lower frequencies (1 and 0.5 Hz) showed either no difference or mixed effects. Thirteen PICOs included 52 primary studies rated as “potentially better,” and four of these PICOs involved 13 primary studies that were also included in a high-quality meta-analysis. In accordance with the AMSTAR-2 quality assessment, the interventions in these four PICOs were considered beneficial in most cases. Nine PICOs included 18 primary studies with different findings in different SRs and were rated as “mixed,” implying that the interventions in these eight PICOs had limited confidence in the effect estimates, and the true effect may be different from the study reports (Miake-Lye et al., 2019). One PICO conclusion was rated as “unclear” because its effect was not reported in the SR (Yang and Chang, 2020) with a critically low quality. Eight PICOs included 17 primary studies that concluded that rTMS showed no difference compared with controls. Of these, six studies showed a potentially better effect of rTMS in short-term follow-up but no difference during long-term follow up (Supplementary Material 4 and Supplementary Material 5). After studies that were ineffective during follow-up were excluded, 8 of 11 primary studies were also included by a high-quality meta-analysis. This finding indicated less effectiveness of these intervention protocols or inapplicability to a particular NP, and the treatment effects could be uncertain. Two PICOs included two primary studies that showed a “potentially worse” conclusion.

FIGURE 5

Discussion

Principal Findings of Evidence Mapping

This evidence map included 40 SRs, and the majority of the primary studies included were RCTs, which is the best study design to assess the effectiveness of interventions (Sylvester et al., 2017). Evidence mapping provided a broad overview of the available evidence of rTMS on NP, showing the focus and counting contributions of available studies by categorizing and generalizing them to help interpret the published SRs. (1) Research gaps: The included SRs covered most types of NP, including SCI, CPSP, CRPS, PLP, DNP, and headache; however, this left an evidence gap of the rTMS for some specific types of NP, such as postherpetic pain, radiculopathy pain, trigeminal neuralgia, post-traumatic brain injury pain, and cancer-related NP. In addition, the control groups were mostly given sham stimulation. Open questions about the effectiveness of rTMS associated with other therapies (such as pharmacotherapy, neurorehabilitation, and psychotherapy) are recommended. Future SRs are needed to analyze immediate, short-term, and long-term effects, which may help clarify the sessions of rTMS. Stimulation parameters, namely, frequency and intensity variable time, are also the direction for further research. (2) Summarization and classification of evidence: Evidence mapping showed that 5–20 Hz, high-frequency rTMS of M1 with short (1–5), medium (6–10), or long (>10) sessions usually lead to a “potentially better” conclusion compared with sham stimulation, suggesting that these interventions are beneficial in most cases. By contrast, the synthesis results for the low frequencies (1 and 0.5 Hz) showed no difference or were mixed, meaning these intervention protocols may be less effective or inappropriate for some specific NPs. (3) The impact of the quality of the SRs on the strength of evidence: Some PICOs from high-quality SRs drew a potentially better conclusion, suggesting that these interventions were beneficial in most cases. Similarly, some PICOs from high-quality SRs did not show any difference in the conclusion, indicating that these interventions may be less effective or inappropriate for some specific NPs. This evidence map is not intended to replace any clinical protocol or guidelines, nor is it intended to provide a standardized protocol. Therefore, the clinical diagnosis of each patient, the existing alternatives, cost-effectiveness, available resources, and other factors must be carefully considered before offering any recommendation (Nussbaumer-Streit et al., 2018).

Comparison of Results of Systematic Reviews

By comparing the results of the SRs, the same PICOs obtained from SRs were presented with different conclusions in the evidence map. The possible reasons were as follows: (1) some studies that reported different sessions had varied effects of rTMS. For example, a good outcome could be found in the short term, but not in the long term, that led to a mixed conclusion. Future SRs should focus on follow-up and explore the long-term effectiveness of the intervention. (2) Some SRs conducted meta-analysis but some did not. Qualitative studies may arrive at conclusions different from those in quantitative studies. For example, a primary study by Onesti et al. (2013) and meta-analysis of Zeng et al. (2020) had a “no difference” conclusion, while the review of Yang and Chang (2020), which only mentioned pain relief, showed a “potentially better” conclusion. The final conclusion in the evidence map of Onesti et al.’s study was “mixed.” (3) Populations with different diseases that cause NP could cause heterogeneity. Previous studies have indicated that patients with orofacial pain have a better analgesic response than those with CPSP, SCI, or BPL (Lefaucheur et al., 2004). For example, a primary study on patients with CRPS (Picarelli et al., 2010) by Chang et al. (2020) and another one involving chronic pain by O’Connell et al. (2018) did not reach the same conclusion. This gap could also be a caveat to provide more reliable and reproducible data. Future studies must consider including more homogeneous groups of participants or stratifying patients in accordance with clinical characteristics and underlying pathogenesis.

If different SRs with varied conclusions included some primary studies that were overlapping and some unique studies, future investigations could synthesize studies that were included in these reviews and find new outcomes including all potential evidence. From the “mixed” results, future investigations could focus on comparing different stimulation protocols (doses, sessions, variable time, and intervals among sessions) of rTMS on NP.

Overall Completeness and Validity of Evidence Mapping

We evaluated the quality of SRs and the credibility of the results of SRs with a new version of AMSTAR. Compared with the previous version, AMSTAR-2 was adapted to include SRs on the basis of RCTs or non-randomized intervention studies or both and provide more refined and rigorous evaluation item criteria. Assessment in this field suggested room for improving SRs’ quality. Future SRs should place more emphasis on the following domains to improve the quality of studies and the validity of the results: reporting an explicit statement about the description of the methodology prior to conducting the review; any significant deviations from the protocol should be justified; explaining the selection of the study designs for inclusion in the review; providing a list of excluded studies and justifying the exclusions; indicating the sources of funding or support for the individual studies included in the SRs; and interpreting or discussing the effect of the risk of bias in individual studies on the total effect.

Strengths and Limitations of This Evidence Mapping

This evidence map may be the first on rTMS for NP. Evidence mapping is a relatively new tool for the synthesis of available evidence, so we explain the methodology and results in more detail compared with published evidence maps and provide all the data of our study process to facilitate the reader’s understanding and use. To avoid selection and data extraction bias, we constructed a rich search string for retrieving from four different databases. In addition, the reference lists of the selected studies were manually scanned for the detection of additional relevant studies, minimizing the risk of missing relevant studies. Study selection and data extraction were made via a double confirmation. Two authors conducted the process of selecting and extracting separately from one another, and any disagreements were then discussed with a third researcher until a final agreement was reached. Furthermore, results were mapped using various graphs, such as bubble plots, heat maps, and tables, which helped improve traceability between the extracted data and the conclusion.

Certain limitations in this evidence map should be considered. First, the map only chose studies published in English, which limited the scope of evidence mapping. Second, given that only SRs were included as a source of evidence, some studies, such as newly published or studies included in these SRs, could have been missed. Third, the methodologies of some SRs had limitations. Furthermore, several different types of studies in SRs comparing therapeutic interventions for NP were included. Although most trials were RCTs, some case reports and observational, open-label, and cohort studies were also available. Finally, evidence mapping synthesized the SRs as a unit rather than individual studies, which could lead to some primary studies being repeated.

Conclusion

Neuropathic pain is a complex and refractory group of diseases. Evidence mapping showed that rTMS, as a compliant and safety neuromodulation treatment, is promising for the treatment of NP. Evidence mapping could encourage clinicians and professionals involved in related areas, such as pain, neurology, psychiatry, and anesthesiology, to pay more attention to non-pharmacological treatments on patients with NPs, especially those with drug resistance. Evidence mapping is a useful and reliable method to identify the currently available evidence on therapeutic interventions and pinpoint gaps to suggest future research. In the future, when designing treatment protocols, rehabilitation practitioners are recommended to consider the duration and sessions of rTMS. More research efforts are needed to highlight the optimal stimulation protocols and standardize all parameters to fill evidence gaps, and more homogeneous groups of participants should be considered. Meanwhile, as the methodological quality of most included SRs scored “critically low,” further efforts are needed to improve the methodological quality and reporting process of SRs.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Statements

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

Author contributions

YZa, YoZ, and YiZ were designed the study. YZa and XL were collected the screening studies, extraction data and charted under the guidance of YoZ. YZa and YoZ analyzed the data and drafted the manuscript. YiZ reviewed the results. SG, YY, JG, and YiZ revised the manuscript for important intellectual content. All authors approved the final version of the manuscript.

Funding

This work was supported by National Natural Science Foundation of China Project (No. 81860875).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnhum.2021.743846/full#supplementary-material

References

  • 1

    AamirA.GirachA.SarrigiannisP. G.HadjivassiliouM.PaladiniA.VarrassiG.et al (2020). Repetitive magnetic stimulation for the management of peripheral neuropathic pain: a systematic review.Adv. Ther.379981012. 10.1007/s12325-020-01231-2

  • 2

    AhmedM. A.DarwishE. S.KhedrE. M.El SerogyY. M.AliA. M. (2012). Effects of low versus high frequencies of repetitive transcranial magnetic stimulation on cognitive function and cortical excitability in Alzheimer’s dementia.J. Neurol.2598392. 10.1007/s00415-011-6128-4

  • 3

    AhmedM. A.MohamedS. A.SayedD. (2011). Long-term antalgic effects of repetitive transcranial magnetic stimulation of motor cortex and serum beta-endorphin in patients with phantom pain.Neurol. Res.33953958. 10.1179/1743132811Y.0000000045

  • 4

    AkyuzG.GirayE. (2019). Noninvasive neuromodulation techniques for the management of phantom limb pain: a systematic review of randomized controlled trials.Int. J. Rehabil. Res.42110. 10.1097/mrr.0000000000000317

  • 5

    Ambriz-TututiM.Alvarado-ReynosoB.Drucker-ColinR. (2016). Analgesic effect of repetitive transcranial magnetic stimulation (rTMS) in patients with chronic low back pain.Bioelectromagnetics37527535. 10.1002/bem.22001

  • 6

    Andre-ObadiaN.MagninM.Garcia-LarreaL. (2011). On the importance of placebo timing in rTMS studies for pain relief.Pain15212331237. 10.1016/j.pain.2010.12.027

  • 7

    Andre-ObadiaN.MagninM.SimonE.Garcia-LarreaL. (2018). Somatotopic effects of rTMS in neuropathic pain? A comparison between stimulation over hand and face motor areas.Eur. J. Pain22707715. 10.1002/ejp.1156

  • 8

    Andre-ObadiaN.MertensP.GueguenA.PeyronR.Garcia-LarreaL. (2008). Pain relief by rTMS: differential effect of current flow but no specific action on pain subtypes.Neurology71833840. 10.1212/01.wnl.0000325481.61471.f0

  • 9

    Andre-ObadiaN.MertensP.Lelekov-BoissardT.AfifA.MagninM.Garcia-LarreaL.et al (2014). Is Life better after motor cortex stimulation for pain control?Results at long-term and their prediction by preoperative rTMS.Pain Phys.175362. 10.36076/ppj.2014/17/53

  • 10

    Andre-ObadiaN.PeyronR.MertensP.MauguièreF.LaurentB.Garcia-LarreaL. (2006). Transcranial magnetic stimulation for pain control. Double-blind study of different frequencies against placebo, and correlation with motor cortex stimulation efficacy.Clin. Neurophysiol.11715361544. 10.1016/j.clinph.2006.03.025

  • 11

    AttalN.AyacheS. S.De AndradeD. C.MhallaA.BaudicS.JazatF. (2016). Repetitive transcranial magnetic stimulation and transcranial direct-current stimulation in neuropathic pain due to radiculopathy: a randomized sham-controlled comparative study.Pain15712241231. 10.1097/j.pain.0000000000000510

  • 12

    AyacheS. S.AhdabR.ChalahM. A.FarhatW. H.MyliusV.GoujonC.et al (2016). Analgesic effects of navigated motor cortex rTMS in patients with chronic neuropathic pain.Eur. J. Pain2014131422. 10.1002/ejp.864

  • 13

    BallesterosM.MonteroN.López-PousaA.UrrútiaG.SolàI.RadaG.et al (2017). Evidence mapping based on systematic reviews of therapeutic interventions for gastrointestinal stromal tumors (GIST).BMC Med. Res. Methodol.17:135. 10.1186/s12874-017-0402-9

  • 14

    BoldtI.Eriks-HooglandI.BrinkhofM. W. G.de BieR.JoggiD.von ElmE. (2014). Non-pharmacological interventions for chronic pain in people with spinal cord injury.Cochrane Database of Syst. Rev.28:CD009177. 10.1002/14651858.CD009177.pub2

  • 15

    BraggeP.ClavisiO.TurnerT.TavenderE.CollieA.GruenR. L. (2011). The Global Evidence Mapping Initiative: scoping research in broad topic areas.BMC Med. Res. Methodol.11:92. 10.1186/1471-2288-11-92

  • 16

    Cardenas-RojasA.Pacheco-BarriosK.Giannoni-LuzaS.Rivera-TorrejonO.FregniF. (2020). Noninvasive brain stimulation combined with exercise in chronic pain: a systematic review and meta-analysis.Exp. Rev. Neurother.20401412. 10.1080/14737175.2020.1738927

  • 17

    CervigniM.OnestiE.CeccantiM.GoriM. C.TartagliaG.CampagnaG.et al (2018). Repetitive transcranial magnetic stimulation for chronic neuropathic pain in patients with bladder pain syndrome/interstitial cystitis.Neurourol. Urodyn.3726782687. 10.1002/nau.23718

  • 18

    ChangM. C.KwakS. G.ParkD. (2020). The effect of rTMS in the management of pain associated with CRPS.Transl. Neurosci.11363370. 10.1515/tnsci-2020-0120

  • 19

    ChenC. C.ChuangY. F.HuangA. C.ChenC. K.ChangY. J. (2016). The antalgic effects of non-invasive physical modalities on central post-stroke pain: a systematic review.J. Phys. Ther. Sci.2813681373. 10.1589/jpts.28.1368

  • 20

    ChoiG. S.ChangM. C. (2018). Effects of high-frequency repetitive transcranial magnetic stimulation on reducing hemiplegic shoulder pain in patients with chronic stoke: a randomized controlled trial. Int. J. Neurosci.128, 110116. 10.1080/00207454.2017.1367682

  • 21

    ChoiG. S.KwakS. G.LeeH. D.ChangM. C. (2018). Effect of high-frequency repetitive transcranial magnetic stimulation on chronic central pain after mild traumatic brain injury: a pilot study. J. Rehabil. Med.50, 246252. 10.2340/16501977-2321

  • 22

    CollocaL.LudmanT.BouhassiraD.BaronR.DickensonA. H.YarnitskyD.et al (2017). Neuropathic pain.Nat. Rev. Dis. Primers.3:17002. 10.1038/nrdp.2017.2

  • 23

    CossinsL.OkellR. W.CameronH.SimpsonB.PooleH. M.GoebelA. (2013). Treatment of complex regional pain syndrome in adults: a systematic review of randomized controlled trials published from June 2000 to February 2012.Eur. J. Pain17158173. 10.1002/j.1532-2149.2012.00217.x

  • 24

    CraggJ. J.WarnerF. M.FinnerupN. B.JensenM. P.MercierC.RichardsJ. S.et al (2016). Meta-analysis of placebo responses in central neuropathic pain: impact of subject, study, and pain characteristics.Pain157530540. 10.1097/j.pain.0000000000000431

  • 25

    CruccuG.Garcia-LarreaL.HanssonP.KeindlM.LefaucheurJ. P.PaulusW.et al (2016). EAN guidelines on central neurostimulation therapy in chronic pain conditions.Eur. J. Neurol.2314891499. 10.1111/ene.13103

  • 26

    DefrinR.GrunhausL.ZamirD.ZeiligG. (2007). The effect of a series of repetitive transcranial magnetic stimulations of the motor cortex on central pain after spinal cord injury.Arch. Phys. Med. Rehabil.8815741580. 10.1016/j.apmr.2007.07.025

  • 27

    FengY.ZhangB.ZhangJ.YinY. (2019). Effects of non-invasive brain stimulation on headache intensity and frequency of headache attacks in patients with migraine: a systematic review and meta-analysis.Headache5914361447. 10.1111/head.13645

  • 28

    FinnerupN. B.AttalN.HaroutounianS.McNicolE.BaronR.DworkinR. H.et al (2015). Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis.Lancet Neurol.14162173. 10.1016/s1474-4422(14)70251-0

  • 29

    FricovaJ.KlirovaM.MasopustV.NovakT.VerebovaK.RokytaR. (2013). Repetitive transcranial magnetic stimulation in the treatment of chronic orofacial pain.Physiol. Res.62S125S134.

  • 30

    GaertnerM.KongJ. T.ScherrerK. H.FooteA.MackeyS.JohnsonK. A. (2018). Advancing transcranial magnetic stimulation methods for complex regional pain syndrome: an open-label study of paired theta burst and high-frequency stimulation.Neuromodulation21409416. 10.1111/ner.12760

  • 31

    GalhardoniR.CorreiaG. S.AraujoH.YengL. T.FernandesD. T.KaziyamaH. H.et al (2015). Repetitive transcranial magnetic stimulation in chronic pain: a review of the literature.Arch. Phys. Med. Rehabil.96S156S172. 10.1016/j.apmr.2014.11.010

  • 32

    GaoF.ChuH.LiJ.YangM.DuL.LiJ.et al (2017). Repetitive transcranial magnetic stimulation for pain after spinal cord injury: a systematic review and meta-analysis.J. Neurosurg. Sci.61514522. 10.23736/s0390-5616.16.03809-1

  • 33

    GatzinskyK.BerghC.LiljegrenA.SilanderH.SamuelssonJ.SvanbergT.et al (2020). Repetitive transcranial magnetic stimulation of the primary motor cortex in management of chronic neuropathic pain: a systematic review.Scand. J. Pain21821. 10.1515/sjpain-2020-0054

  • 34

    GoudraB.ShahD.BaluG.GoudaG.BaluA.BorleA.et al (2017). Repetitive transcranial magnetic stimulation in chronic pain: a meta-analysis.Anesth. Essays Res.11751757. 10.4103/aer.AER_10_17

  • 35

    GrantM. J.BoothA. (2009). A typology of reviews: an analysis of 14 review types and associated methodologies.Health Info Libr. J.2691108. 10.1111/j.1471-1842.2009.00848.x

  • 36

    GromischE. S.KernsR. D.BeauvaisJ. (2020). Pain-related illness intrusiveness is associated with lower activity engagement among persons with multiple sclerosis.Mult. Scler. Relat. Disord.38101882. 10.1016/j.msard.2019.101882

  • 37

    HaddawayN. R.BernesC.JonssonB. G.HedlundK. (2016). The benefits of systematic mapping to evidence-based environmental management.Ambio45613620. 10.1007/s13280-016-0773-x

  • 38

    HamidP.MalikB. H.HussainM. L. (2019). Noninvasive transcranial magnetic stimulation (TMS) in chronic refractory pain: a systematic review.Cureus11:e6019. 10.7759/cureus.6019

  • 39

    HenssenD. J. H. A.HoefslootW.GroenenP. S. M.Van Cappellen van WalsumA. M.KurtE.KoziczT. (2019). Bilateral vs. unilateral repetitive transcranial magnetic stimulation to treat neuropathic orofacial pain: a pilot study.Brain Stimul.12803805. 10.1016/j.brs.2019.02.001

  • 40

    Herrero BabiloniA.GuayS.NixdorfD. R.de BeaumontL.LavigneG. (2018). Non-invasive brain stimulation in chronic orofacial pain: a systematic review.J. Pain Res.1114451457. 10.2147/jpr.S168705

  • 41

    HirayamaA.SaitohY.KishimaH.ShimokawaT.OshinoS.HirataM.et al (2006). Reduction of intractable deafferentation pain by navigation-guided repetitive transcranial magnetic stimulation of the primary motor cortex.Pain1222227. 10.1016/j.pain.2005.12.001

  • 42

    HosomiK.ShimokawaT.IkomaK.NakamuraY.SugiyamaK.UgawaY.et al (2013). Daily repetitive transcranial magnetic stimulation of primary motor cortex for neuropathic pain: a randomized, multicenter, double-blind, crossover, sham-controlled trial.Pain15410651072. 10.1016/j.pain.2013.03.016

  • 43

    IrlbacherK.KuhnertJ.Ro richtS.MeyerB. U.BrandtS. A. (2006). Central and peripheral deafferent pain: therapy with repetitive transcranial magnetic stimulation.Nervenarzt7711961203. 10.1007/s00115-006-2148-1

  • 44

    JettéF.CoteI.MezianeH. B.MercierC. (2013). Effect of single-session repetitive transcranial magnetic stimulation applied over the hand versus leg motor area on pain after spinal cord injury.Neurorehabil. Neural. Repair27636643. 10.1177/1545968313484810

  • 45

    JinY.XingG.LiG.WangA.FengS.TangQ.et al (2015). High frequency repetitive transcranial magnetic stimulation therapy for chronic neuropathic pain: a meta-analysis.Pain Phys.18E1029E1046.

  • 46

    JohnsonS.SummersJ.PridmoreS. (2006). Changes to somatosensory detection and pain thresholds following high frequency repetitive TMS of the motor cortex in individuals suffering from chronic pain.Pain123187192. 10.1016/j.pain.2006.02.030

  • 47

    KaliaL. V.O’ConnorP. W. (2005). Severity of chronic pain and its relationship to quality of life in multiple sclerosis.Mult. Scler.11322327. 10.1191/1352458505ms1168oa

  • 48

    KalitaJ.BhoiS. K.MisraU. K. (2017). Effect of high rate rTMS on somatosensory evoked potential in migraine.Cephalalgia3712221230. 10.1177/0333102416675619

  • 49

    KalitaJ.LaskarS.BhoiS. K.MisraU. K. (2016). Efficacy of single versus three sessions of high rate repetitive transcranial magnetic stimulation in chronic migraine and tension-type headache.J. Neurol.26322382246. 10.1007/s00415-016-8257-2

  • 50

    KangB. S.ShinH. I.BangM. S. (2009). Effect of repetitive transcranial magnetic stimulation over the hand motor cortical area on central pain after spinal cord injury.Arch. Phys. Med. Rehabil.9017661771. 10.1016/j.apmr.2009.04.008

  • 51

    KhedrE. M.KotbH. I.MostafaM. G.MohamadM. F.AmrS. A.AhmedM. A.et al (2015). Repetitive transcranial magnetic stimulation in neuropathic pain secondary to malignancy: a randomized clinical trial.Eur. J. Pain19519527. 10.1002/ejp.576

  • 52

    KhedrE. M.KotbH.KamelN. F.AhmedM. A.SadekR.RothwellJ. C. (2005). Long-lasting analgic effects of daily sessions of repetitive transcranial magnetic stimulation in central and peripheral neuropathic pain.J. Neurol. Neurosurg. Psychiatry76833838. 10.1136/jnnp.2004.055806

  • 53

    KleinM. M.TreisterR.RaijT.Pascual-LeoneA.ParkL.NurmikkoT.et al (2015). Transcranial magnetic stimulation of the brain: guidelines for pain treatment research.Pain15616011614. 10.1097/j.pain.0000000000000210

  • 54

    KobayashiM.FujimakiT.MiharaB.OhiraT. (2015). Repetitive transcranial magnetic stimulation once a week induces sustainable long-term relief of central poststroke pain.Neuromodulation18249254. 10.1111/ner.12301

  • 55

    KohútováB.FricováJ.KlírováM.NovákT.RokytaR. (2017). Theta burst stimulation in the treatment of chronic orofacial pain: a randomized controlled trial. Physiol. Res.66, 10411047. 10.33549/physiolres.933474

  • 56

    KumarB.KalitaJ.KumarG.MisraU. K. (2009). Central poststroke pain: a review of pathophysiology and treatment.Anesthesia Anal.10816451657. 10.1213/ane.0b013e31819d644c

  • 57

    KumruH.AlbuS.VidalJ.TormosJ. M. (2017). Effectiveness of repetitive trancranial or peripheral magnetic stimulation in neuropathic pain.Disabil. Rehabil.39856866. 10.3109/09638288.2016.1170213

  • 58

    LanL.ZhangX.LiX.RongX.PengY. (2017). The efficacy of transcranial magnetic stimulation on migraine: a meta-analysis of randomized controlled trails.J. Headache Pain1886. 10.1186/s10194-017-0792-4

  • 59

    LangM.TreisterR.KleinM. M.OaklanderA. L. (2014). Repetitive transcranial magnetic stimulation (rTMS) of the primary motor cortex for treating facial neuropathic pain-preliminary results of arandomized, sham-controlled, cross-over study.Mol. Pain10:6. 10.1111/j.1526-4637.2009.00657.x

  • 60

    LawsonM. A.FrankS.ZafarN.WaschkeA.KalffR.ReichartR. (2018). Time course of the response to navigated repetitive transcranial magnetic stimulation at 10 Hz in chronic neuropathic pain.Neurol. Res.40564572. 10.1080/01616412.2018.1453636

  • 61

    LefaucheurJ. P. (2003). Evaluation électrophysiologique des boucles réflexes spinales potentiellement impliquées dans la spasticité [Electrophysiological assessment of reflex pathways involved in spasticity]. Neurochirurgie49, 205214.

  • 62

    LefaucheurJ. P.AlemanA.BaekenC.BenningerD. H.BrunelinJ.Di LazzaroV.et al (2020). Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): an update (2014-2018).Clin. Neurophysiol.131474528. 10.1016/j.clinph.2019.11.002

  • 63

    LefaucheurJ. P.AyacheS. S.SorelM.FarhatW. H.ZouariH. G.Ciampi de AndradeD. (2012). Analgesic effects of repetitive transcranial magnetic stimulation of the motor cortex in neuropathic pain: influence of theta burst stimulation priming.Eur. J. Pain1614031413. 10.1002/j.1532-2149.2012.00150.x

  • 64

    LefaucheurJ. P.DrouotX.KeravelY.NguyenJ. P. (2001a). Pain relief induced by repetitive transcranial magnetic stimulation of precentral cortex. Neuroreport12, 29632965. 10.1097/00001756-200109170-00041

  • 65

    LefaucheurJ. P.DrouotX.NguyenJ. P. (2001b). Interventional neurophysiology for pain control: duration of pain relief following repetitive transcranial magnetic stimulation of the motor cortex.Neurophysiol. Clin.31247252. 10.1016/s0987-7053(01)00260-x

  • 66

    LefaucheurJ. P.DrouotX.Menard-LefaucheurI.KeravelY.NguyenJ. P. (2008). Motor cortex rTMS in chronic neuropathic pain: pain relief is associated with thermal sensory perception improvement.J. Neurol. Neurosurg. Psychiatry7910441049. 10.1136/jnnp.2007.135327

  • 67

    LefaucheurJ. P.DrouotX.Menard-LefaucheurI.ZerahF.BendibB.CesaroP.et al (2004). Neurogenic pain relief by repetitive transcranial magnetic cortical stimulation depends on the origin and the site of pain.J. Neurol. Neurosurg. Psychiatry75612616. 10.1136/jnnp.2003.022236

  • 68

    LefaucheurJ. P.HatemS.NinebA.Ménard-LefaucheurI.WendlingS.KeravelY.et al (2006). Somatotopic organization of the analgesic effects of motor cortex rTMS in neuropathic pain.Neurology6719982004. 10.1212/01.wnl.0000247138.85330.88

  • 69

    LefaucheurJ. P.Menard-LefaucheurI.GoujonC.KeravelY.NguyenJ. P. (2011). Predictive value of rTMS in the identification of responders to epidural motor cortex stimulation therapy for pain.J. Pain1211021111. 10.1016/j.jpain.2011.05.004

  • 70

    LeungA.DonohueM.XuR.LeeR.LefaucheurJ. P.KhedrE. M.et al (2009). rTMS for suppressing neuropathic pain: a meta-analysis.J. Pain1012051216. 10.1016/j.jpain.2009.03.010

  • 71

    LeungA.ShuklaS.FallahA.SongD.LinL.GolshanS.et al (2016). Repetitive transcranial magnetic stimulation in managing mild traumatic brain injury-related headaches.Neuromodulation19133141. 10.1111/ner.12364

  • 72

    LiampasA.RekatsinaM.VadaloucaA.PaladiniA.VarrassiG.ZisP. (2020b). Non-pharmacological management of painful peripheral neuropathies: a systematic review.Adv. Ther.3740964106. 10.1007/s12325-020-01462-3

  • 73

    LiampasA.VelidakisN.GeorgiouT.VadaloucaA.VarrassiG.HadjigeorgiouG. M.et al (2020a). Prevalence and management challenges in central post-stroke neuropathic pain: a systematic review and meta-analysis.Adv. Ther.3732783291. 10.1007/s12325-020-01388-w

  • 74

    LinH.LiW.NiJ.WangY. (2018). Clinical study of repetitive transcranial magnetic stimulation of the motor cortex for thalamic pain.Medicine97:e11235. 10.1097/md.0000000000011235

  • 75

    MaS. M.NiJ. X.LiX. Y.YangL. Q.GuoY. N.TangY. Z. (2015). High-frequency repetitive transcranial magnetic stimulation reduces pain in postherpetic neuralgia.Pain Med.1621622170. 10.1111/pme.12832

  • 76

    Madera AnayaM.FrancoJ. V. A.BallesterosM.SolàI.Urrútia CuchíG.Bonfill CospX. (2019). Evidence mapping and quality assessment of systematic reviews on therapeutic interventions for oral cancer.Cancer Manag. Res.11117130. 10.2147/cmar.S186700

  • 77

    MalaveraA.SilvaF. A.FregniF.CarrilloS.GarciaR. G. (2016). Repetitive transcranial magnetic stimulation for phantom limb pain in land mine victims: a double-blinded, randomized, sham-controlled trial.J. Pain.17911918. 10.1016/j.jpain.2016.05.003

  • 78

    MalaveraM.SilvaF.GarciaR.QuirosJ.DallosM.PinzonA. (2013). Effects of transcranial magnetic stimulation in the treatment of phantom limb pain in landmine victims: a randomized clinical trial.J. Neurol. Sci.333:e534. 10.1016/j.jns.2013.07.1880

  • 79

    MatsumuraY.HirayamaT.YamamotoT. (2013). Comparison between pharmacologic evaluation and repetitive transcranial magnetic stimulation-induced analgesia in poststroke pain patients.Neuromodulation16349354. 10.1111/ner.12019

  • 80

    MehtaS.OrenczukK.McIntyreA.WillemsG.WolfeD. L.HsiehJ. T.et al (2013). Neuropathic pain post spinal cord injury part 1: systematic review of physical and behavioral treatment.Top. Spinal. Cord. Inj. Rehabil.196177. 10.1310/sci1901-61

  • 81

    MelchiorC.GourcerolG.ChastanN.VerinE.MenardJ. F.DucrotteP.et al (2014). Effect of transcranial magnetic stimulation on rectal sensitivity in irritable bowel syndrome: a randomized, placebo-controlled pilot study.Colorectal. Dis.16O104O111. 10.1111/codi.12450

  • 82

    MelchiorM.ChastangJ. F.HeadJ.GoldbergM.ZinsM.NabiH.et al (2013). Socioeconomic position predicts long-term depression trajectory: a 13-year follow-up of the GAZEL cohort study.Mol. Psychiatry18112121. 10.1038/mp.2011.116

  • 83

    Miake-LyeI. M.HempelS.ShanmanR.ShekelleP. G. (2016). What is an evidence map? A systematic review of published evidence maps and their definitions, methods, and products.Syst Rev.528. 10.1186/s13643-016-0204-x

  • 84

    Miake-LyeI. M.MakS.LeeJ.LugerT.TaylorS. L.ShanmanR.et al (2019). Massage for pain: an evidence map.J. Alter. Comple. Med.25475502. 10.1089/acm.2018.0282

  • 85

    MisraU. K.KalitaJ.TripathiG. M.BhoiS. K. (2013). Is beta endorphin related to migraine headache and its relief?Cephalalgia33316322. 10.1177/0333102412473372

  • 86

    MisraU. K.KalitaJ.TripathiG.BhoiS. K. (2017). Role of beta endorphin in pain relief following high rate repetitive transcranial magnetic stimulation in migraine.Brain Stimul.10618623. 10.1016/j.brs.2017.02.006

  • 87

    MoissetX.BouhassiraD.Avez CouturierJ.AlchaarH.ConradiS.DelmotteM. H.et al (2020b). Pharmacological and non-pharmacological treatments for neuropathic pain: systematic review and French recommendations.Rev. Neurol.176325352. 10.1016/j.neurol.2020.01.361

  • 88

    MoissetX.PereiraB.de AndradeD.FontaineD.Lantéri-MinetM.MawetJ. (2020a). Neuromodulation techniques for acute and preventive migraine treatment: a systematic review and meta-analysis of randomized controlled trials.J. Headache Pain21:142. 10.1186/s10194-020-01204-4

  • 89

    Moreno-DuarteI.MorseL. R.AlamM.BiksonM.ZafonteR.FregniF. (2014). Targeted therapies using electrical and magnetic neural stimulation for the treatment of chronic pain in spinal cord injury.NeuroImage8510031013. 10.1016/j.neuroimage.2013.05.097

  • 90

    MullaS. M.WangL.KhokharR.IzharZ.AgarwalA.CoubanR.et al (2015). Management of central poststroke pain: systematic review of randomized controlled trials.Stroke4628532860. 10.1161/strokeaha.115.010259

  • 91

    NardoneR.VersaceV.SebastianelliL.BrigoF.ChristovaM.ScaranoG. I.et al (2019). Transcranial magnetic stimulation in subjects with phantom pain and non- painful phantom sensations: a systematic review.Brain Res. Bull.14819. 10.1016/j.brainresbull.2019.03.001

  • 92

    NurmikkoT.MacIverK.BresnahanR.HirdE.NelsonA.SaccoP. (2016). Motor cortex reorganization and repetitive transcranial magnetic stimulation for pain-a methodological study.Neuromodulation19669678. 10.1111/ner.12444

  • 93

    Nussbaumer-StreitB.GrillichL.GlechnerA.AffengruberL.GartlehnerG.MorcheJ.et al (2018). [GRADE: evidence to Decision (EtD) frameworks - a systematic and transparent approach to making well informed healthcare choices. 1: Introduction].Z. Evid. Fortbild. Qual. Gesundhwes.1345766. 10.1016/j.zefq.2018.05.004

  • 94

    O’ConnellN. E.MarstonL.SpencerS.DesouzaL. H.WandB. M. (2018). Non-invasive brain stimulation techniques for chronic pain.Cochrane Database Syst. Rev.4:CD008208. 10.1002/14651858.CD008208.pub5

  • 95

    OnestiE.GabrieleM.CambieriC.CeccantiM.RaccahR.Di StefanoG.et al (2013). H-coil repetitive transcranial magnetic stimulation for pain relief in patients with diabetic neuropathy.Eur. J. Pain1713471356. 10.1002/j.1532-2149.2013.00320.x

  • 96

    Pacheco-BarriosK.MengX.FregniF. (2020). Neuromodulation techniques in phantom limb pain: a systematic review and meta-analysis.Pain Med.2123102322. 10.1093/pm/pnaa039

  • 97

    PapanasN.ZieglerD. (2016). Emerging drugs for diabetic peripheral neuropathy and neuropathic pain.Exp. Opin. Emerg. Drugs21393407. 10.1080/14728214.2016.1257605

  • 98

    PaulusW.PeterchevA. V.RiddingM. (2013). Transcranial electric and magnetic stimulation: technique and paradigms.Handb. Clin. Neurol.116329342. 10.1016/b978-0-444-53497-2.00027-9

  • 99

    PeiQ.WuB.TangY.YangX.SongL.WangN.et al (2019). Repetitive transcranial magnetic stimulation at different frequencies for postherpetic neuralgia: a double-blind, sham-controlled,randomized trial.Pain Phys.22E303E313.

  • 100

    PetersenK.VakkalankaS.KuzniarzL. (2015). Guidelines for conducting systematic mapping studies in software engineering: an update.Inform. Softw. Technol.64118. 10.1016/j.infsof.2015.03.007

  • 101

    PicarelliH.TeixeiraM. J.de AndradeD. C.MyczkowskiM. L.LuvisottoT. B.YengL. T.et al (2010). Repetitive transcranial magnetic stimulation is efficacious as an add-on to pharmacological therapy in complex regional pain syndrome (CRPS) type I.J. Pain.1112031210. 10.1016/j.jpain.2010.02.006

  • 102

    Pinot-MonangeAMoissetXChauvetPGremeauASComptourACanisMet al (2019). Repetitive transcranial magnetic stimulation therapy. (rTMS) for endometriosis patients with refractory pelvic chronic pain: a pilot study.J. Clin. Med.8:508. 10.3390/jcm8040508

  • 103

    PlegerB.JanssenF.SchwenkreisP.VolkerB.MaierC.TegenthoffM. (2004). Repetitive transcranial magnetic stimulation of the motor cortex attenuates pain perception in complex regional pain syndrome type I.Neurosci. Lett.3568790. 10.1016/j.neulet.2003.11.037

  • 104

    PommierB.Creac’hC.BeauvieuxV.NutiC.VassalF.PeyronR. (2016). Robot-guided neuronavigated rTMS as an alternative therapy for central. (neuropathic) pain: clinical experience and long-term follow-up.Eur. J. Pain20907916. 10.1002/ejp.815

  • 105

    QuesadaC.PommierB.FauchonC.BradleyC.Créac’hC.VassalF.et al (2018). Robot-guided neuronavigated repetitive transcranial magnetic stimulation. (rTMS) in Central neuropathic pain.Arch. Phys. Med. Rehabil.9922032215. 10.1016/j.apmr.2018.04.013

  • 106

    RamgerB. C.BaderK. A.DaviesS. P.StewartD. A.LedbetterL. S.SimonC. B.et al (2019). Effects of non-invasive brain stimulation on clinical pain intensity and experimental pain sensitivity among individuals with central post-stroke pain: a systematic review.J. Pain Res.1233193329. 10.2147/JPR.S216081

  • 107

    RollnikJ. D.WustefeldS.DauperJ.KarstM.FinkM.KossevA.et al (2002). Repetitive transcranial magnetic stimulation for the treatment of chronic pain – a pilot study.Eur. Neurol.48610.

  • 108

    SaitohY.HirayamaA.KishimaH.OshinoS.HirataM.KatoA.et al (2006). Stimulation of primary motor cortex for intractable deafferentation pain. Acta Neurochir. Suppl.99, 5759. 10.1007/978-3-211-35205-2_11

  • 109

    SaitohY.HirayamaA.KishimaH.ShimokawaT.OshinoS.HirataM.et al (2007). Reduction of intractable deafferentation pain due to spinal cord or peripheral lesion by high-frequency repetitive transcranial magnetic stimulation of the primary motor cortex.J. Neurosurg.107555559. 10.3171/jns-07/09/0555

  • 110

    SheaB. J.ReevesB. C.WellsG.ThukuM.HamelC.MoranJ.et al (2017). AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both.BMJ358j4008. 10.1136/bmj.j4008

  • 111

    ShehataH. S.EsmailE. H.AbdelalimA.El-JaafaryS.ElmaznyA.SabbahA.et al (2016). Repetitive transcranial magnetic stimulation versus botulinum toxin injection in chronic migraine prophylaxis: a pilot randomized trial.J. Pain Res.9771777. 10.2147/JPR.S116671

  • 112

    ShenZ.LiZ.KeJ.HeC.LiuZ.ZhangD.et al (2020). Effect of non-invasive brain stimulation on neuropathic pain following spinal cord injury: a systematic review and meta-analysis.Medicine99:e21507. 10.1097/md.0000000000021507

  • 113

    ShimizuT.HosomiK.MaruoT.GotoY.YokoeM.KageyamaY.et al (2017). Efficacy of deep rTMS for neuropathic pain in the lower limb: a randomized, double-blind crossover trial of an H-coil and figure-8 coil.J. Neurosurg.12711721180. 10.3171/2016.9.JNS16815

  • 114

    StillingJ. M.MonchiO.AmoozegarF.DebertC. T. (2019). Transcranial magnetic and direct current stimulation (TMS/tDCS) for the treatment of headache: a systematic review.Headache59339357. 10.1111/head.13479

  • 115

    SylvesterR. J.CanfieldS. E.LamT. B.MarconiL.MacLennanS.YuanY.et al (2017). Conflict of evidence: resolving discrepancies when findings from randomized controlled trials and meta-analyses disagree.Eur. Urol.71811819. 10.1016/j.eururo.2016.11.023

  • 116

    TeoW. P.KannanA.LohP. K.ChewE.SharmaV. K.ChanY. C. (2014). Tolerance of motor cortex rTMS in chronic migraine.J. Clin. Diagn. Res.8MM01MM02.

  • 117

    UritsI.AdamianL.FiocchiJ.HoytD.ErnstC.KayeA. D.et al (2019). Advances in the understanding and management of chronic pain in multiple sclerosis: a comprehensive review.Curr. Pain Headache Rep.23:59. 10.1007/s11916-019-0800-2

  • 118

    YangS.ChangM. C. (2020). Effect of repetitive transcranial magnetic stimulation on pain management: a systematic narrative review.Front. Neurol.11:114. 10.3389/fneur.2020.00114

  • 119

    YilmazB.KesikburunS.YasarE.TanA. K. (2014). The effect of repetitive transcranial magnetic stimulation on refractory neuropathic pain in spinal cord injury.J. Spinal. Cord. Med.37397400.

  • 120

    YuB.QiuH.LiJ.ZhongC.LiJ. (2020). Noninvasive brain stimulation does not improve neuropathic pain in individuals with spinal cord injury: evidence from a meta-analysis of 11 randomized controlled trials.Am. J. Phys. Med. Rehabil.99811820. 10.1097/phm.0000000000001421

  • 121

    ZaghiS.ThieleB.PimentelD.PimentelT.FregniF. (2011). Assessment and treatment of pain with non-invasive cortical stimulation.Restorat. Neurol. Neurosci.29439451. 10.3233/RNN-2011-0615

  • 122

    ZengH.Pacheco-BarriosK.CaoY.LiY.ZhangJ.YangC.et al (2020). Non-invasive neuromodulation effects on painful diabetic peripheral neuropathy: a systematic review and meta-analysis.Sci Rep.10:19184. 10.1038/s41598-020-75922-9

  • 123

    ZucchellaC.MantovaniE.De IccoR.TassorelliC.SandriniG.TamburinS. (2020). Non-invasive brain and spinal stimulation for pain and related symptoms in multiple sclerosis: a systematic review.Front. Neurosci.14:547069. 10.3389/fnins.2020.547069

Summary

Keywords

neuropathic pain, non-pharmacological, repetitive transcranial magnetic stimulation, evidence mapping, evidence synthesis, motor cortex

Citation

Zang Y, Zhang Y, Lai X, Yang Y, Guo J, Gu S and Zhu Y (2022) Evidence Mapping Based on Systematic Reviews of Repetitive Transcranial Magnetic Stimulation on the Motor Cortex for Neuropathic Pain. Front. Hum. Neurosci. 15:743846. doi: 10.3389/fnhum.2021.743846

Received

02 August 2021

Accepted

15 November 2021

Published

16 February 2022

Volume

15 - 2021

Edited by

Kai Wang, Anhui Medical University, China

Reviewed by

Joaquim Pereira Brazil-Neto, Unieuro, Brazil; Gong-Jun Ji, Anhui Medical University, China

Updates

Copyright

*Correspondence: Yi Zhu,

†These authors have contributed equally to this work

This article was submitted to Brain Imaging and Stimulation, a section of the journal Frontiers in Human Neuroscience

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics